PMID- 37314298
OWN - NLM
STAT- MEDLINE
DCOM- 20230616
LR  - 20230701
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 51
IP  - 6
DP  - 2023 Jun
TI  - Sorafenib as first-line treatment for patients with primary hepatocellular 
      carcinoma: an outcome evaluation.
PG  - 3000605231179928
LID - 10.1177/03000605231179928 [doi]
LID - 03000605231179928
AB  - OBJECTIVE: To evaluate the clinical outcomes following first-line treatment with 
      sorafenib in patients with primary hepatocellular carcinoma (HCC). METHODS: This 
      retrospective cohort study enrolled patients with primary HCC that had been 
      treated with sorafenib. Their data were collected from the hospital medical 
      records database at three time-points: after three cycles, after six cycles and 
      at the end of the sorafenib treatment regimen. The starting dose was 800 mg/day 
      sorafenib but this could be reduced to 600 mg/day or 400 mg/day if patients 
      developed adverse events (AEs). RESULTS: A total of 98 patients participated in 
      the study. Of these, nine (9.2%) had a partial response, 47 patients (48.0%) had 
      stable disease and 42 patients (42.9%) had progressive disease. The overall 
      disease control rate was 57.1% (56 of 98 patients). Median progression-free 
      survival for the overall cohort was 4.7 months. The most common AEs were 
      hand-foot skin reaction (49 of 98 patients; 50.0%), fatigue (41 of 98 patients; 
      41.8%), appetite loss (39 of 98 patients; 39.8%) and hepatotoxicity/transaminitis 
      (24 of 98 patients; 24.5%). The majority of the AEs were toxicity grades 1 and 2. 
      CONCLUSION: Sorafenib as a first-line treatment for primary HCC patients provided 
      survival benefits and the AEs were well tolerated by patients.
FAU - Nguyen, Dung Thi
AU  - Nguyen DT
AUID- ORCID: 0000-0001-5798-8636
AD  - Department of On-demand GI Medical Oncology, Hanoi Oncology Hospital, Hanoi, 
      Vietnam.
FAU - Nguyen, Duong Hoang
AU  - Nguyen DH
AD  - Department of On-demand GI Medical Oncology, Hanoi Oncology Hospital, Hanoi, 
      Vietnam.
FAU - Nguyen, Van Thi Hong
AU  - Nguyen VTH
AD  - Department of On-demand GI Medical Oncology, Hanoi Oncology Hospital, Hanoi, 
      Vietnam.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Sorafenib/therapeutic use
MH  - Retrospective Studies
MH  - *Liver Neoplasms/drug therapy
MH  - Outcome Assessment, Health Care
PMC - PMC10291016
OTO - NOTNLM
OT  - Hepatocellular carcinoma (HCC)
OT  - grade, adverse event (AE)
OT  - progression free survival (PFS)
OT  - response rate
OT  - sorafenib
OT  - toxicity
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2023/06/14 13:06
MHDA- 2023/06/16 06:42
PMCR- 2023/06/14
CRDT- 2023/06/14 09:43
PHST- 2023/06/16 06:42 [medline]
PHST- 2023/06/14 13:06 [pubmed]
PHST- 2023/06/14 09:43 [entrez]
PHST- 2023/06/14 00:00 [pmc-release]
AID - 10.1177_03000605231179928 [pii]
AID - 10.1177/03000605231179928 [doi]
PST - ppublish
SO  - J Int Med Res. 2023 Jun;51(6):3000605231179928. doi: 10.1177/03000605231179928.